A southwest oncology group phase i study of the sequential combination of recombinant interferon-γ and recombinant interleukin-2 in patients with cancer

Charles W. Taylor, Ellen M. Chase, Robert P. Whitehead, John J. Rinehart, John J. Rinerhart, James A. Neidhart, Rene Gonzalez, Paul A. Bunn, Evan M. Hersh

Research output: Contribution to journalArticle

11 Scopus citations

Abstract

Thirty-seven patients with advanced malignancies were treated sequentially with recombinant interferon-γ (rIFN-γ) and recombinant interleukin-2 (rIL-2) in an outpatient dose escalation clinical trial. rIFN-γ (0.1 or 0.25 mg/m2/day) was administered by intramuscular injection, days 1–7 and rIL-2 (12, 18, or 24 x 106IU/m2/day) was administered by a 15-min intravenous bolus, days 8–12. Common toxicities encountered included fever, chills, fatigue, neutropenia, and elevations of SGOT, bilirubin, or creatinine. Hypotension and cardiac and pulmonary toxicities were rare. With repeated cycles of therapy, nausea/vomiting and diarrhea associated with the administration of rIL-2 were seen in greater frequency. There were no treatment-related deaths, and no patient required intensive care unit admission for toxicity management. A complete response was observed in one of 11 patients with renal cancer and a partial response was observed in one of seven patients with malignant melanoma. Due to problems with drug supply, further dose escalation could not be continued, and maximum tolerated doses (MTD) were not determined by strict criteria. However, the combination of rIFN-γ, 0.25 mg/m2/day, and rIL-2, 24 x 106IU/m2/day, appeared to be beyond the MTD, as three of six patients at this dose level could not complete one cycle of therapy due to toxicity, and for further study using this schedule, we recommend the doses: Rifn-γ, 0.1 mg/m2/day, and rIL-2, 24 x 106IU/m2/day.

Original languageEnglish (US)
Pages (from-to)176-183
Number of pages8
JournalJournal of Immunotherapy
Volume11
Issue number3
DOIs
StatePublished - Apr 1992

Keywords

  • Interferon-γ
  • Interleukin-2
  • Phase I study-Malignant melanoma
  • Renal cancer

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Pharmacology
  • Cancer Research

Fingerprint Dive into the research topics of 'A southwest oncology group phase i study of the sequential combination of recombinant interferon-γ and recombinant interleukin-2 in patients with cancer'. Together they form a unique fingerprint.

  • Cite this